Latest NmVac4-A/C/Y/W-135 Stories
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide BASEL, Switzerland, Jan.
FORT MYERS, Fla., Jan. 23, 2015 /PRNewswire/ -- Today the U.S.
ATLANTA, Oct. 29, 2014 /PRNewswire/ -- The U.S.
ATLANTA, Sept. 19, 2014 /PRNewswire/ -- This week, a student at Georgetown University died from serogroup B meningococcal disease.
Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination SWIFTWATER, Pa., Sept.
Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/
Report Identifies Challenges and Includes Recommendations for Management of Future Meningococcal Disease Outbreaks Bethesda, Maryland (PRWEB) May 22, 2014
ALBANY, New York, May 9, 2014 /PRNewswire/ -- According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate,
DORVAL QC, Feb.
- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb.